Illumina Q2 revenue falls 3%, but beats expectations

Illumina

31/07/2025 21:43

Overview

Illumina Q2 fiscal revenue falls 3% yr/yr, but beats analysts' expectations, per LSEG data

Adjusted EPS beats expectations, per LSEG data

Co announces agreement to acquire SomaLogic, expanding strategic footprint

Outlook

Illumina expects FY 2025 revenue decline of 2.5% to 0.5%

Company raises FY 2025 non-GAAP EPS guidance to $4.45-$4.55

Illumina sees FY 2025 non-GAAP operating margin at 22%-22.5%

Result Drivers

X CONSUMABLES - Continued ramp in X consumables drove revenue results, per CEO Jacob Thaysen

CLINICAL SEGMENT - Accelerating growth in clinical segment, Illumina's largest customer base, contributed to results

OPERATIONAL EXCELLENCE - Focus on operational excellence helped drive margin expansion, per CEO Jacob Thaysen

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.06 bln
$1.05 bln (19 Analysts)
Q2 Adjusted EPS
Beat
$1.19
$1.01 (21 Analysts)
Q2 EPS
$1.49
Q2 Adjusted Net Income
Beat
$187 mln
$160.90 mln (17 Analysts)
Q2 Net Income
$235 mln
Q2 Gross Margin
65.6%
Q2 Adjusted EBIT Margin
23.8%
Q2 Adjusted Gross Margin
69.4%
Q2 EBIT Margin
20.2%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy", 12 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Illumina Inc is $105.00, about 1.6% below its July 30 closing price of $106.66

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nPn40gK1Ca

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)